CD14 and metastatic melanoma: “HLA DR on CD14− CD16+ monocytes” represents the expression of monocytes in peripheral blood, where CD14+ CD16− HLA DR monocytes have been reported as predictive factors for the response to anti-PD-1 immunotherapy in metastatic melanoma (Krieg et al., 2018).